JP2008521928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521928A5 JP2008521928A5 JP2007544545A JP2007544545A JP2008521928A5 JP 2008521928 A5 JP2008521928 A5 JP 2008521928A5 JP 2007544545 A JP2007544545 A JP 2007544545A JP 2007544545 A JP2007544545 A JP 2007544545A JP 2008521928 A5 JP2008521928 A5 JP 2008521928A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- medicament
- group
- medicament according
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims description 10
- 230000001613 neoplastic Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 108010034143 Inflammasomes Proteins 0.000 claims description 5
- 101700079133 KLK7 Proteins 0.000 claims description 4
- 101700076891 PAPA Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000011885 synergistic combination Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 32
- 201000011510 cancer Diseases 0.000 claims 18
- 239000002246 antineoplastic agent Substances 0.000 claims 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 9
- 201000009251 multiple myeloma Diseases 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 210000003169 Central Nervous System Anatomy 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 229910052740 iodine Chemical group 0.000 claims 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 4
- 239000011630 iodine Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrugs Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 3
- 210000000133 Brain Stem Anatomy 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 Dexamethasone Drugs 0.000 claims 3
- 229960004679 Doxorubicin Drugs 0.000 claims 3
- 206010017758 Gastric cancer Diseases 0.000 claims 3
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 3
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 3
- 206010038038 Rectal cancer Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- 229960003433 Thalidomide Drugs 0.000 claims 3
- 206010046766 Uterine cancer Diseases 0.000 claims 3
- 229960001467 bortezomib Drugs 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 201000011231 colorectal cancer Diseases 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 201000003733 ovarian melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000009381 skin hemangioma Diseases 0.000 claims 3
- 201000003708 skin melanoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000002195 synergetic Effects 0.000 claims 1
- 0 CC(C1CC*)(C2(C(C3C=CCCC3)O)NC1=O)OC2=O Chemical compound CC(C1CC*)(C2(C(C3C=CCCC3)O)NC1=O)OC2=O 0.000 description 8
Description
本発明の別の態様は、少なくとも2つのプロテアソーム阻害薬の相乗的組合せを腫瘍性疾患患者に投与することを包含する、腫瘍性疾患の治療方法である。
Claims (37)
- Xが塩素である、請求項1に記載の医薬。
- 前記腫瘍性疾患が癌である、請求項1〜3のいずれか1項に記載の医薬。
- 前記癌が乳癌、肉腫、白血病、卵巣癌、子宮癌、膀胱癌、前立腺癌、結腸癌、直腸癌、胃癌、肺癌、リンパ腫、多発性骨髄腫、膵臓癌、肝臓癌、腎臓癌、内分泌癌、皮膚癌、黒色腫、血管腫、及び脳又は中枢神経系(CNS)癌から成る群から選択される、請求項4に記載の医薬。
- 前記癌が多発性骨髄腫、結腸直腸癌、前立腺癌、乳腺癌、非小細胞肺癌及び卵巣癌又は黒色腫から成る群から選択される、請求項5に記載の医薬。
- 前記癌が多発性骨髄腫である、請求項6に記載の医薬。
- 前記患者がヒトである、請求項1〜7のいずれか1項に記載の医薬。
- 前記他の化学療法剤がデキサメタゾン、ドキソルビシン及びサリドマイドから成る群から選択される、請求項1〜8のいずれか1項に記載の医薬。
- 前記他の化学療法剤がプロテアソーム阻害薬である、請求項1〜8のいずれか1項に記載の医薬。
- 前記他の化学療法剤がボルテゾミブである、請求項10に記載の医薬。
- Xが塩素である、請求項12に記載の医薬。
- 前記腫瘍性疾患が癌である、請求項12〜14のいずれか1項に記載の医薬。
- 前記癌が乳癌、肉腫、白血病、卵巣癌、子宮癌、膀胱癌、前立腺癌、結腸癌、直腸癌、胃癌、肺癌、リンパ腫、多発性骨髄腫、膵臓癌、肝臓癌、腎臓癌、内分泌癌、皮膚癌、黒色腫、血管腫、及び脳又は中枢神経系(CNS)癌から成る群から選択される、請求項15に記載の医薬。
- 前記癌が多発性骨髄腫、結腸直腸癌、前立腺癌、乳腺癌、非小細胞肺癌及び卵巣癌又は黒色腫から成る群から選択される、請求項16に記載の医薬。
- 前記癌が多発性骨髄腫である、請求項17に記載の医薬。
- 前記患者がヒトである、請求項12〜18のいずれか1項に記載の医薬。
- 前記他の化学療法剤がデキサメタゾン、ドキソルビシン及びサリドマイドから成る群から選択される、請求項12〜19のいずれか1項に記載の医薬。
- 前記他の化学療法剤がプロテアソーム阻害薬である、請求項12〜19のいずれか1項に記載の医薬。
- 前記他の化学療法剤がボルテゾミブである、請求項21に記載の医薬。
- 前記組合せが相乗的である、請求項12〜22のいずれか1項に記載の医薬。
- 前記組合せが相加的である、請求項12〜22のいずれか1項に記載の医薬。
- Xが塩素である、請求項25に記載の薬学的組成物。
- 前記他の化学療法剤がデキサメタゾン、ドキソルビシン及びサリドマイドから成る群から選択される、請求項25〜27のいずれか1項に記載の薬学的組成物。
- 前記他の化学療法剤がプロテアソーム阻害薬である、請求項25〜27のいずれか1項に記載の薬学的組成物。
- 前記他の化学療法剤がボルテゾミブである、請求項29に記載の薬学的組成物。
- 少なくとも2つのプロテアソーム阻害薬の相乗的組合せを含む、腫瘍性疾患患者における腫瘍性疾患を治療するための医薬。
- 前記腫瘍性疾患が癌である、請求項31に記載の医薬。
- 前記癌が乳癌、肉腫、白血病、卵巣癌、子宮癌、膀胱癌、前立腺癌、結腸癌、直腸癌、胃癌、肺癌、リンパ腫、多発性骨髄腫、膵臓癌、肝臓癌、腎臓癌、内分泌癌、皮膚癌、黒色腫、血管腫、及び脳又は中枢神経系(CNS)癌から成る群から選択される、請求項32に記載の医薬。
- 前記癌が多発性骨髄腫、結腸直腸癌、前立腺癌、乳腺癌、非小細胞肺癌及び卵巣癌又は黒色腫から成る群から選択される、請求項33に記載の医薬。
- 前記癌が多発性骨髄腫である、請求項34に記載の医薬。
- 前記患者がヒトである、請求項31〜35のいずれか1項に記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63316104P | 2004-12-03 | 2004-12-03 | |
US60/633,161 | 2004-12-03 | ||
PCT/US2005/043668 WO2006060676A1 (en) | 2004-12-03 | 2005-12-02 | Compositions and methods for treating neoplastic diseases |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012198263A Division JP5837469B2 (ja) | 2004-12-03 | 2012-09-10 | 腫瘍性疾患を治療するための組成物及び方法 |
JP2014228602A Division JP5963830B2 (ja) | 2004-12-03 | 2014-11-11 | 腫瘍性疾患を治療するための組成物及び方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008521928A JP2008521928A (ja) | 2008-06-26 |
JP2008521928A5 true JP2008521928A5 (ja) | 2009-01-22 |
JP5676071B2 JP5676071B2 (ja) | 2015-02-25 |
Family
ID=36118298
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007544545A Active JP5676071B2 (ja) | 2004-12-03 | 2005-12-02 | 腫瘍性疾患を治療するための組成物及び方法 |
JP2012198263A Active JP5837469B2 (ja) | 2004-12-03 | 2012-09-10 | 腫瘍性疾患を治療するための組成物及び方法 |
JP2014228602A Active JP5963830B2 (ja) | 2004-12-03 | 2014-11-11 | 腫瘍性疾患を治療するための組成物及び方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012198263A Active JP5837469B2 (ja) | 2004-12-03 | 2012-09-10 | 腫瘍性疾患を治療するための組成物及び方法 |
JP2014228602A Active JP5963830B2 (ja) | 2004-12-03 | 2014-11-11 | 腫瘍性疾患を治療するための組成物及び方法 |
Country Status (18)
Country | Link |
---|---|
US (5) | US20070225350A1 (ja) |
EP (1) | EP1830838B1 (ja) |
JP (3) | JP5676071B2 (ja) |
KR (1) | KR101282191B1 (ja) |
CN (2) | CN101155582B (ja) |
AU (1) | AU2005311709B2 (ja) |
BR (1) | BRPI0517135B1 (ja) |
CA (1) | CA2588923C (ja) |
DK (1) | DK1830838T3 (ja) |
ES (1) | ES2396762T3 (ja) |
HK (1) | HK1113462A1 (ja) |
IL (3) | IL183506A (ja) |
MX (1) | MX2007006526A (ja) |
NZ (1) | NZ555439A (ja) |
PL (1) | PL1830838T3 (ja) |
SG (1) | SG157365A1 (ja) |
WO (1) | WO2006060676A1 (ja) |
ZA (1) | ZA200704402B (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7144723B2 (en) * | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
DE602004031614D1 (de) * | 2003-06-20 | 2011-04-14 | Nereus Pharmaceuticals Inc | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
US8217072B2 (en) * | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
JP2007535559A (ja) * | 2004-04-30 | 2007-12-06 | ネレアス ファーマシューティカルズ インコーポレイテッド | [3.2.0]複素環式化合物及びその使用法 |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
MX2007006523A (es) * | 2004-12-03 | 2007-09-11 | Nereus Pharmaceuticals Inc | Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos. |
KR101282191B1 (ko) | 2004-12-03 | 2013-07-08 | 다나-파버 캔서 인스티튜트 인크. | 신생물성 질환을 치료하는 조성물 및 방법 |
CA2937005A1 (en) * | 2005-03-22 | 2006-09-28 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
BRPI0618198A2 (pt) * | 2005-11-04 | 2018-06-26 | Nereus Pharmaceuticals Inc | métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia |
AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
BRPI0707826B1 (pt) | 2006-02-14 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Compostos inibidores de histona desacetilase, composição farmacêutica e uso dos referidos compostos |
CN101460457B (zh) | 2006-04-06 | 2012-07-18 | 尼瑞斯药品公司 | Salinosporamide a及其类似物的全合成 |
US8304451B2 (en) | 2006-05-03 | 2012-11-06 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
WO2008124699A1 (en) * | 2007-04-06 | 2008-10-16 | Nereus Pharmaceuticals, Inc. | A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer |
US20080280968A1 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
JP2011514352A (ja) | 2008-03-07 | 2011-05-06 | ネレアス ファーマシューティカルズ インコーポレイテッド | サリノスポラミドaおよびその類似体の全合成 |
AU2009246467A1 (en) | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
WO2009146546A1 (en) * | 2008-06-06 | 2009-12-10 | University Health Network | 8-hydroxyquinoline derivatives for the treatment of hematological malignancies |
CA2731730C (en) | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
EP2318830A4 (en) * | 2008-08-13 | 2011-09-07 | George Mason Intellectual Prop | THERAPEUTIC EX-VIVO SCREENING OF LIVING BONE MARROW CELLS ON MULTIPLE MYELOME |
US20110319427A1 (en) * | 2009-03-05 | 2011-12-29 | University Health Network | Use of 5ahq and bortezomib for the treatment of hematological diseases |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
US10679309B2 (en) | 2011-12-30 | 2020-06-09 | Elwha Llc | Evidence-based healthcare information management protocols |
US10528913B2 (en) | 2011-12-30 | 2020-01-07 | Elwha Llc | Evidence-based healthcare information management protocols |
US10475142B2 (en) | 2011-12-30 | 2019-11-12 | Elwha Llc | Evidence-based healthcare information management protocols |
US10559380B2 (en) | 2011-12-30 | 2020-02-11 | Elwha Llc | Evidence-based healthcare information management protocols |
US20130173294A1 (en) | 2011-12-30 | 2013-07-04 | Elwha LLC, a limited liability company of the State of Delaware | Evidence-based healthcare information management protocols |
US10552581B2 (en) | 2011-12-30 | 2020-02-04 | Elwha Llc | Evidence-based healthcare information management protocols |
KR20150087270A (ko) * | 2012-11-05 | 2015-07-29 | 프로나이 테라퓨틱스, 인코포레이티드 | Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법 |
AU2016349833A1 (en) * | 2015-11-06 | 2018-05-24 | Accuitis Pharmaceuticals, Inc. | Use of proteasome inhibitors to treat ocular disorders |
WO2018033631A1 (en) | 2016-08-19 | 2018-02-22 | Celgene International Ii Sàrl | Morphic forms of marizomib and uses thereof |
JP2020505470A (ja) * | 2017-01-31 | 2020-02-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | NGly1を阻害する薬剤及びその使用方法 |
JP7498475B2 (ja) | 2020-01-31 | 2024-06-12 | 株式会社セラバイオファーマ | 多発性骨髄腫の治療剤 |
CN113750215B (zh) * | 2021-09-24 | 2023-06-23 | 暨南大学 | 用于治疗肿瘤的联合药物 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
DE4039602A1 (de) * | 1990-12-12 | 1992-06-17 | Bauer Kurt Heinz Prof Dr | Pharmazeutische formulierungen |
KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
EP1500393A1 (en) * | 1992-11-27 | 2005-01-26 | Mayne Pharma (USA) Inc. | Injectable composition containing taxol |
US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
PT721335E (pt) * | 1993-10-01 | 2005-11-30 | Roche Palo Alto Llc | Suspensoes orais em altas doses de micofenolato de mofetil |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US6838477B2 (en) * | 1995-04-12 | 2005-01-04 | President And Fellows Of Harvard College | Lactacystin analogs |
US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US5667809A (en) * | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) * | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
NZ337364A (en) | 1997-02-15 | 2001-06-29 | Millennium Pharm Inc | Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB |
US5922683A (en) * | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
WO1999006353A1 (fr) * | 1997-08-04 | 1999-02-11 | Taisho Pharmaceutical Co., Ltd. | Derives aryloxyaniline |
US6133308A (en) * | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
BR9811304A (pt) | 1997-08-15 | 2001-11-13 | Francois Soucy | Sìntese de clasto-lactacistina" beta"-lactona eseus análogos |
EP1017398A1 (en) | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
US20010051654A1 (en) * | 1997-09-25 | 2001-12-13 | Elliott Peter J. | Treatment of inflammatory and autoimmune diseases |
US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
CA2310664C (en) * | 1997-11-21 | 2008-03-11 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6333323B1 (en) * | 1998-03-26 | 2001-12-25 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
US6509331B1 (en) * | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
BR9914648A (pt) | 1998-10-20 | 2001-11-27 | Millennium Pharm Inc | Processo para monitorar ação medicamentosa deinibidor de proteasoma |
FR2784988B1 (fr) * | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20020049157A1 (en) | 1999-08-25 | 2002-04-25 | Jiangping Wu | Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
CA2425632A1 (en) | 2000-10-12 | 2002-04-18 | Viromics Gmbh | Agents for the treatment of viral infections |
US7144723B2 (en) * | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
DE10316735A1 (de) * | 2002-04-05 | 2003-11-20 | Viromics Gmbh | Mittel zur Behandlung von Flaviviridae-Infektionen |
US7176232B2 (en) * | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7179834B2 (en) * | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
WO2004043374A2 (en) | 2002-11-06 | 2004-05-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
DE602004024037D1 (de) | 2003-02-14 | 2009-12-24 | Intermed Discovery Gmbh | Substituierte heterozyklen |
DE602004031614D1 (de) * | 2003-06-20 | 2011-04-14 | Nereus Pharmaceuticals Inc | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
US8217072B2 (en) * | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
WO2005094423A2 (en) | 2004-02-26 | 2005-10-13 | President And Fellows Of Harvard College | Selective inhibition of proteasomes of tuberculosis and other bacteria |
US7371875B2 (en) * | 2004-03-12 | 2008-05-13 | Miikana Therapeutics, Inc. | Cytotoxic agents and methods of use |
WO2005099687A2 (en) * | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
US7183417B2 (en) * | 2004-04-09 | 2007-02-27 | President And Fellows Of Harvard College | Simple stereocontrolled synthesis of salinosporamide A |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
JP2007535559A (ja) | 2004-04-30 | 2007-12-06 | ネレアス ファーマシューティカルズ インコーポレイテッド | [3.2.0]複素環式化合物及びその使用法 |
US20060264495A1 (en) * | 2004-04-30 | 2006-11-23 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US7579371B2 (en) * | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
KR20070041742A (ko) | 2004-07-12 | 2007-04-19 | 바이엘 크롭사이언스 아게 | 살진균제 및 살충제로서의 치환된 2-피롤리돈 유도체 |
WO2006060609A1 (en) | 2004-12-03 | 2006-06-08 | Honeywell International Inc. | Gas jet control for inertial measurement unit |
KR101282191B1 (ko) | 2004-12-03 | 2013-07-08 | 다나-파버 캔서 인스티튜트 인크. | 신생물성 질환을 치료하는 조성물 및 방법 |
MX2007006523A (es) * | 2004-12-03 | 2007-09-11 | Nereus Pharmaceuticals Inc | Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos. |
WO2006060819A2 (en) | 2004-12-03 | 2006-06-08 | The Regents Of The University Of California | Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells |
WO2006118973A2 (en) | 2005-04-29 | 2006-11-09 | Nereus Pharmaceuticals, Inc. | Methods of using heterobyclic compounds for treatment of rectal cancer |
US20060287520A1 (en) * | 2005-05-16 | 2006-12-21 | Danishefsky Samuel J | Synthesis of salinosporamide A and analogues thereof |
EP1931679A4 (en) | 2005-08-10 | 2009-07-29 | Harvard College | ANALOGUE OF SALINOSPORAMIDE A |
WO2007030662A1 (en) * | 2005-09-09 | 2007-03-15 | Nereus Pharmaceuticals, Inc. | Biosynthesis of salinosporamide a and its analogs |
US7465720B2 (en) | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
BRPI0618198A2 (pt) * | 2005-11-04 | 2018-06-26 | Nereus Pharmaceuticals Inc | métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia |
GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
CN101460457B (zh) | 2006-04-06 | 2012-07-18 | 尼瑞斯药品公司 | Salinosporamide a及其类似物的全合成 |
WO2007130404A1 (en) | 2006-05-03 | 2007-11-15 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
US8088923B2 (en) * | 2006-07-07 | 2012-01-03 | The Texas A&M University System | Cyclic-fused beta-lactones and their synthesis |
US20080280968A1 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
JP2011514352A (ja) | 2008-03-07 | 2011-05-06 | ネレアス ファーマシューティカルズ インコーポレイテッド | サリノスポラミドaおよびその類似体の全合成 |
AU2009246467A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
US8772724B2 (en) | 2011-01-05 | 2014-07-08 | Intel-Ge Care Innovations Llc | Low power, inexpensive velocity detection using a PIR array |
-
2005
- 2005-12-02 KR KR1020077015299A patent/KR101282191B1/ko active IP Right Grant
- 2005-12-02 JP JP2007544545A patent/JP5676071B2/ja active Active
- 2005-12-02 PL PL05852783T patent/PL1830838T3/pl unknown
- 2005-12-02 EP EP05852783A patent/EP1830838B1/en active Active
- 2005-12-02 AU AU2005311709A patent/AU2005311709B2/en active Active
- 2005-12-02 BR BRPI0517135-0A patent/BRPI0517135B1/pt active IP Right Grant
- 2005-12-02 CA CA2588923A patent/CA2588923C/en active Active
- 2005-12-02 NZ NZ555439A patent/NZ555439A/en active IP Right Revival
- 2005-12-02 CN CN2005800466157A patent/CN101155582B/zh active Active
- 2005-12-02 US US11/293,354 patent/US20070225350A1/en not_active Abandoned
- 2005-12-02 MX MX2007006526A patent/MX2007006526A/es active IP Right Grant
- 2005-12-02 ES ES05852783T patent/ES2396762T3/es active Active
- 2005-12-02 DK DK05852783.9T patent/DK1830838T3/da active
- 2005-12-02 SG SG200907327-1A patent/SG157365A1/en unknown
- 2005-12-02 WO PCT/US2005/043668 patent/WO2006060676A1/en active Application Filing
- 2005-12-02 CN CN201310024563.XA patent/CN103230394B/zh active Active
-
2007
- 2007-05-29 IL IL183506A patent/IL183506A/en active IP Right Grant
- 2007-05-29 ZA ZA200704402A patent/ZA200704402B/en unknown
-
2008
- 2008-03-11 HK HK08102798.2A patent/HK1113462A1/xx unknown
- 2008-07-30 US US12/183,007 patent/US8722724B2/en active Active
-
2012
- 2012-09-10 JP JP2012198263A patent/JP5837469B2/ja active Active
-
2014
- 2014-03-25 US US14/224,965 patent/US10610517B2/en active Active
- 2014-11-11 JP JP2014228602A patent/JP5963830B2/ja active Active
- 2014-12-24 IL IL23642614A patent/IL236426B/en active IP Right Grant
-
2015
- 2015-09-21 IL IL241756A patent/IL241756A0/en unknown
-
2020
- 2020-02-25 US US16/800,570 patent/US20200206190A1/en not_active Abandoned
-
2022
- 2022-08-18 US US17/890,563 patent/US20230210817A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008521928A5 (ja) | ||
JP2006514689A5 (ja) | 1−オキソ−2−(2,6−ジオキソピペリジン−3−イル)−4−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
JP2019510832A5 (ja) | ||
JP2006523216A5 (ja) | ||
JP2013507415A5 (ja) | ||
TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
JP2005525345A5 (ja) | ||
JP2009514880A5 (ja) | ||
JP2017517548A5 (ja) | ||
JP2018517686A5 (ja) | ||
JP2018535923A (ja) | 胆道癌の治療 | |
JP2009541223A5 (ja) | ||
WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
JP2009514881A5 (ja) | ||
JP2015536986A5 (ja) | ||
JP2008535902A5 (ja) | ||
WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
BRPI0513843A (pt) | composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato | |
RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
JP2015520753A5 (ja) | ||
JP2009506054A5 (ja) | ||
JP2008536853A5 (ja) | ||
JP2016525097A5 (ja) | ||
JP2020523354A5 (ja) | ||
JP2015532296A5 (ja) |